<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
09.01.2020 16:14:00

Why Alnylam Pharmaceuticals Rose 57.9% in 2019

Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) jumped 57.9% last year, according to data provided by S&P Global Market Intelligence. That far exceeded the 28.8% gain of the S&P 500 in 2019, though all of the pharma stock's gains came in the fourth quarter. It was quite the finish considering that the stock got off to a rocky start, collapsing in May after first-quarter 2019 operating results were released. At the time, Alnylam Pharmaceuticals also announced plans to increase research and development spending, which made investors nervous. Could the money-losing business justify that decision with only one drug on the market? Those concerns were short-lived, however, as the company exited the year with two approved drug products, and one or two more headed toward approval in 2020.Image source: Getty Images.Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu Alnylam Pharmaceuticals Inc.mehr Analysen

01.10.18 Alnylam Pharmaceuticals Overweight Cantor Fitzgerald
13.08.18 Alnylam Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
07.08.18 Alnylam Pharmaceuticals Buy Stifel, Nicolaus & Co., Inc.
05.07.18 Alnylam Pharmaceuticals Buy Chardan Capital Markets
04.05.18 Alnylam Pharmaceuticals Hold Stifel, Nicolaus & Co., Inc.

Eintrag hinzufügen

SMI mit neuem Hoch – UBS mit neuem Chef | BX Swiss TV

Aktien in diesem Artikel

Finanzen.net News

pagehit
;